• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Black Diamond Therapeutics, Inc. - Common Stock (NQ:BDTX)

    2.180 -0.080 (-3.54%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jun 2, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,365,305
    Open 2.260
    Bid (Size) 2.200 (300)
    Ask (Size) 2.260 (500)
    Prev. Close 2.260
    Today's Range 2.170 - 2.270
    52wk Range 1.930 - 4.940
    Shares Outstanding 36,213,654
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    What's Going On With Black Diamond Therapeutics Stock Tuesday? ↗
    Black Diamond Therapeutics (NASDAQ: BDTX) stock climbs. Get the latest technical analysis, moving averages, and price action. 
    Via Benzinga
    Which stocks are experiencing notable movement on Friday? ↗
    Via Chartmill

    Performance

    YTD
    -12.4%
    -12.4%
    1 Month
    -19.3%
    -19.3%
    3 Month
    -10.3%
    -10.3%
    6 Month
    -42.2%
    -42.2%
    1 Year
    -8.0%
    -8.0%

    More News

    Read More
    Keep an eye on the top gainers and losers in Friday's session. ↗
    Via Chartmill
    Friday's session: gap up and gap down stocks ↗
    Via Chartmill
    News headline image
    Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study ↗
    Via MarketBeat
    News headline image
    Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals ↗
    Via Benzinga
    News headline image
    Black Diamond (BDTX) Q2 Loss Narrows 47% ↗
    Via The Motley Fool
    News headline image
    Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
    From Black Diamond Therapeutics, Inc
    Via GlobeNewswire
    News headline image
    These stocks have an unusual volume in today's session ↗
    Via Chartmill
    News headline image
    Unusual volume stocks in Thursday's session ↗
    Via Chartmill
    News headline image
    These stocks are the most active in today's session ↗
    Via Chartmill

    Frequently Asked Questions

    Is Black Diamond Therapeutics, Inc. - Common Stock publicly traded?
    Yes, Black Diamond Therapeutics, Inc. - Common Stock is publicly traded.
    What exchange does Black Diamond Therapeutics, Inc. - Common Stock trade on?
    Black Diamond Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock?
    The ticker symbol for Black Diamond Therapeutics, Inc. - Common Stock is BDTX on the Nasdaq Stock Market
    What is the current price of Black Diamond Therapeutics, Inc. - Common Stock?
    The current price of Black Diamond Therapeutics, Inc. - Common Stock is 2.180
    When was Black Diamond Therapeutics, Inc. - Common Stock last traded?
    The last trade of Black Diamond Therapeutics, Inc. - Common Stock was at 06/02/26 04:00 PM ET
    What is the market capitalization of Black Diamond Therapeutics, Inc. - Common Stock?
    The market capitalization of Black Diamond Therapeutics, Inc. - Common Stock is 78.95M
    How many shares of Black Diamond Therapeutics, Inc. - Common Stock are outstanding?
    Black Diamond Therapeutics, Inc. - Common Stock has 79M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.